Welichem announces appointment of President & CEO

    BURNABY, BC, June 27 /CNW/ - Welichem Biotech Inc. (the "Company")
(TSX-V: WBI) today announces the appointment of Dr. Genhui Chen as President &
CEO of the Company, effective immediately. A long time director and one of the
founders of the Company, he will guide Welichem through the next crucial stage
of development as it realizes the potential value of its drug candidates in
clinical trials.
    Dr. John Webster, Interim Chairman of the Company, stated that "He was
very pleased that Dr. Chen had agreed to take up the key leadership role at
Welichem at this time. He has a deep understanding of both the business and
scientific components of the Company and related international experience in
the biotech industry. His commitment and insight will be invaluable."
    York Yingping Guo resigned as President & CEO for personal and family
reasons. Dr. Webster opined that "Welichem Biotech has been very fortunate to
have had York as its President and CEO. The Company has achieved significant
milestones during his tenure and I am very grateful for the great contribution
he has made to the Company."

    About Welichem Biotech Inc.
    Welichem Biotech Inc. is a publicly-traded biotechnology company
developing therapeutic drugs in the fields of autoimmune and inflammatory
diseases and cancer.

    John M. Webster
    Interim Chairman of Board of Directors

    %SEDAR: 00021386E

For further information:

For further information: John M. Webster, Tel.: (604) 432-1703, Email:
info@welichem.com; Yan Chen, Business Development Manager, Tel.: (604)
432-1703, Email: investors@welichem.com

Organization Profile

Welichem Biotech Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890